233 completed, 52 unknown, 40 terminated, 31 recruiting. 96 Phase 3, 94 Phase 4, 72 Phase 2, 33 Not applicable, 24 Phase 1.
Follow Infliximab: new trials by email Literature Review of Infliximab trials Research Report on Infliximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study Infliximab - Checkpoint Inhibitor, Pilot Study | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 14 | 2026-12-31 | 2026-10-16 |
| Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis | Phase 2 | Not yet recruiting | Instituto de Oftalmología Fundación Conde de Valenciana | 38 | 2026-12-01 | 2026-06-26 |
| Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease Azathioprine + infliximab, Intestinal resection - Crohn Disease | Not applicable | Not yet recruiting | Nantes University Hospital | 150 | 2026-10-01 | 2026-06-23 |
| Infliximab for Immune Checkpoint Inhibitor Associated AKI Infliximab, Prednisone, prednisone (oral) - Acute Kidney Injury, Acute Interstitial Nephritis | Phase 4 | Recruiting | Massachusetts General Hospital | 44 | 2026-09-15 | 2026-10-09 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE） upadacitinib, Infliximab - Acute Severe Ulcerative Colitis | Phase 4 | Recruiting | Xijing Hospital of Digestive Diseases | 226 | 2026-04-20 | 2026-04-24 |
| Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease Infliximab, Akkermansia muciniphila + Infliximab - Crohn's Diseases | Phase 4 | Not yet recruiting | Chinese Medical Association | 400 | 2026-04-01 | 2026-02-17 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease Palmitoleic Acid + Infliximab, Infliximab - Crohn's Disease | Phase 4 | Not yet recruiting | Chinese Medical Association | 400 | 2026-04-01 | 2026-02-18 |
| Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab - Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | Not yet recruiting | Assiut University | 95 | 2026-03-01 | 2026-03-27 | |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Infliximab, Adalimumab, Vedolizumab - Inflamatory Bowel Disease, Crohn Disease (CD) | Recruiting | Shanghai 10th People's Hospital | 198 | 2026-01-16 | 2026-07-10 | |
| Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial Infliximab, Tofacitinib - Acute Severe Ulcerative Colitis | Phase 2 | Not yet recruiting | Asian Institute of Gastroenterology, India | 60 | 2026-01-01 | 2025-12-24 |
| EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis Methoxsalen, Infliximab, Vedolizumab - Immune-related Colitis | Phase 2 | Withdrawn | Therakos LLC | 2025-12-15 | 2025-12-26 | |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest. Infliximab, Sodium chloride injection USP, 0.9% (placebo) - Cardiac Arrest (CA), Post Cardiac Arrest Syndrome | Not applicable | Active not recruiting | Peking University Third Hospital | 208 | 2025-10-01 | 2026-06-10 |
| Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study Fecal microbiota transplantation, infliximab - Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation | Not applicable | Active not recruiting | Shanghai 10th People's Hospital | 94 | 2025-08-01 | 2025-09-02 |
Showing 20 of 397. Sign in to see all of them.
Crohn Disease (94) · Arthritis, Rheumatoid (87) · Colitis, Ulcerative (58) · Inflammatory Bowel Diseases (42) · Spondylitis, Ankylosing (35) · Psoriasis (27) · Arthritis, Psoriatic (18) · Arthritis (7) · COVID-19 (7) · Inflammation (7) · Melanoma (7) · Mucocutaneous Lymph Node Syndrome (7) · Spondylarthritis (7) · Colitis (6) · Graft vs Host Disease (6)
Merck Sharp & Dohme LLC (46) · Centocor, Inc. (23) · Pfizer (11) · Celltrion (10) · Sixth Affiliated Hospital, Sun Yat-sen University (7) · Centocor Ortho Biotech Services, L.L.C. (5) · Children's Hospital of Fudan University (5) · Emory University (5) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (5) · Massachusetts General Hospital (5) · Assistance Publique - Hôpitaux de Paris (4) · Erasmus Medical Center (4) · Medical University of Vienna (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Nichi-Iko Pharmaceutical Co., Ltd. (4)
United States (99) · Canada (33) · France (30) · China (29) · Belgium (24) · Germany (23) · United Kingdom (23) · Netherlands (21) · South Korea (19) · Italy (17) · Spain (17) · Israel (16) · Denmark (15) · Czechia (14) · Japan (13)
Edmund K Li, MD (3) · Ying Huang (3) · Amit Assa, MD (2) · David Laharie (2) · Farzin Forooghian, MD (2) · James Chodosh, MD, MPH (2) · Jane C Burns, M.D. (2)
PMID 40013523, PMID 19596014, PMID 30524702, PMID 16339095, PMID 17324131, PMID 17476675, PMID 24339699, PMID 25173754, PMID 27696724, PMID 32905628, PMID 34216825, PMID 36607544, PMID 38788861, PMID 39134391, PMID 40243842, PMID 41849243, PMID 41986154, PMID 10228190, PMID 10446825, PMID 11096166, PMID 11604419, PMID 12047962, PMID 1382099, PMID 14762776, PMID 14985485, PMID 14987462, PMID 15389187, PMID 15476155, PMID 15517638, PMID 15692973, PMID 15788779, PMID 15888152, PMID 16009830, PMID 16083527, PMID 16226614, PMID 16406545, PMID 16461435, PMID 16508926, PMID 16545455, PMID 16572442, PMID 16646033, PMID 16704649, PMID 16840744, PMID 16874778, PMID 16960923, PMID 17097378, PMID 17114188, PMID 17290043, PMID 17324398, PMID 17392352
2014 (5), 2005 (4), 2016 (4), 2017 (4), 2009 (3), 2019 (3), 2023 (2), 1UL1RR025780 (1), 2008 (1), 2015 (1), 2018 (1), R01DK132408 (1), R01DK144161 (1), R01MH108605 (1), R01MH112076 (1)